Health outcome | Main source of variation | Population at risk | Period of exposure measurement | n | Fthr | Impact | CI low (€2006) | CI mean (€2006) | CI high (€2006) | Proportion (mean estimate) |
---|---|---|---|---|---|---|---|---|---|---|
Liver cancer | Conversion from ingestion dose to blood chlordecone | All | <2003 | 436 968 | 47 % | 2.5 | 4 174 000 | 6 213 000 | 12 717 000 | 23 % |
≥2003 | 458 465 | 29 % | 0.6 | 951 000 | 1 415 000 | 2 896 000 | 11 % | |||
Annual benefit |  |  | −2.0 | 3 223 000 | 4 798 000 | 9 821 000 | 35 % | |||
Prostate cancer | IC95% of RR | Men > 44 years | <2003 | 72 566 | 64 % | 1.8 | 896 000 | 3 286 000 | 6 742 000 | 12 % |
≥2003 | 76 049 | 34 % | 0.3 | 166 000 | 610 000 | 1 251 000 | 5 % | |||
Annual benefit |  |  | −1.5 | 730 000 | 2 676 000 | 5 491 000 | 20 % | |||
Renal dysfunction | BMD10-HED | Women | <2003 | 227 417 | 31 % | 0.033 | 8 000 | 95 000 | 237 000 | 0.36 % |
≥2003 | 239 470 | 24 % | 0.011 | 3 000 | 31 000 | 77 000 | 0.24 % | |||
Annual benefit |  |  | −0.022 | 5 000 | 64 000 | 160 000 | 0.47 % | |||
Cognitive development | Equivalence between QI point and ASQ point | Male new born | <2003 | 3 747 | 86Â % | 1005.1 | 3 384 000 | 16 922 000 | 33 844 000 | 64Â % |
≥2003 | 3 929 | 64 % | 652.4 | 2 155 000 | 10 779 000 | 21 557 000 | 84 % | |||
Annual benefit |  |  | −352.7 | 1 229 000 | 6 143 000 | 12 287 000 | 45 % | |||
Total |  |  | <2003 |  |  |  | 8 462 000 | 26 516 000 | 53 540 000 | 100 % |
≥2003 |  |  |  | 3 275 000 | 12 835 000 | 25 781 000 | 100 % | |||
Annual benefit |  |  |  | 5 187 000 | 13 681 000 | 27 759 000 | 100 % |